BioNTech presented encouraging clinical data for its late-stage cancer drug candidates Pumitamig and Gotistobart at the ASCO 2026 meeting. Pumitamig showed promising anti-tumor activity in a Phase 2/3 study for first-line treatment of non-small cell lung cancer, while Gotistobart demonstrated sustained anti-tumor effects and survival benefits in platinum-resistant ovarian cancer patients. These results support BioNTech's strategy to develop innovative immunotherapies and antibody-drug conjugates, with over 25 ongoing Phase 2 and 3 trials. The company aims to expand treatment options for cancers with high unmet medical needs through both monotherapies and combination therapies.
